Clinical Trials

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT03761108 2026-04-20

LINKER-MM1

Phase 1/2 Recruiting

387 enrolled 2 FDA

Multiple Myeloma, Recurrence

NCT03777306 2026-04-20

The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma

Phase NA Completed

85 enrolled

Multiple Myeloma

NCT04166565 2026-04-20

EMN19

41 enrolled

Multiple Myeloma

NCT04561492 2026-04-20

PentiMyelo

45 enrolled

Multiple Myeloma

NCT05135351 2026-04-20

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

Phase NA Recruiting

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT05909059 2026-04-20

CAR T-cell Therapy in Patients With Renal Dysfunction

LymphoidOther hematologic neoplasmPlasma cell

20 enrolled

Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05969860 2026-04-20

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

220 enrolled

MyeloidPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes

NCT06179888 2026-04-20

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

78 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Multiple Myeloma

NCT07539233 2026-04-20

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.

24 enrolled

Multiple Myeloma

NCT07280013 2026-04-17

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

60 enrolled

Phase 1 Not yet recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT07537049 2026-04-17

BR101 in Patients With Relapsed/Refractory Multiple Myeloma

10 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT04822337 2026-04-16

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

70 enrolled

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05317416 2026-04-16

MagnetisMM-7

854 enrolled

Hematologic Diseases, Multiple Myeloma

NCT06057402 2026-04-16

MagnetisMM15

Phase 4 Recruiting

80 enrolled

Multiple Myeloma

NCT06083922 2026-04-16

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

20 enrolled

Multiple Myeloma

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

492 enrolled

Phase EARLY_PHASE1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06385652 2026-04-16

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Multiple Myeloma

NCT06418750 2026-04-16

DELICATESSE

Phase NA Completed

20 enrolled

Multiple Myeloma

NCT06484777 2026-04-16

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

138 enrolled

Multiple Myeloma

NCT06523621 2026-04-16

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

1 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma

NCT06870760 2026-04-16

Pre-malignant States to Hematologic Malignancies in Firefighters

Recruiting

300 enrolled

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT07075185 2026-04-16

inMMyCAR

40 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Disease, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT07095452 2026-04-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

660 enrolled

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma

NCT01384513 2026-04-15

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Phase 2 Completed

40 enrolled 15 charts

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mastocytosis, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Polycythemia Vera, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT02420860 2026-04-15

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

113 enrolled

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

67 enrolled

Multiple Myeloma

NCT03710421 2026-04-15

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Multiple Myeloma

NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05434689 2026-04-15

COMMANDER

80 enrolled